BRAF and cutaneous melanoma: BRAF is mutated in about 50% of cutaneous melanomas (1) and in patients with BRAF-mutated metastatic cutaneous melanoma multiple therapeutic options are currently available: BRAF-MEK inhibitors targeted therapies, AntiPD1, and AntiCTLA4 immune checkpoint inhibitors (2, 3).